Avantor® Reports Third Quarter 2025 Results

Core Insights - Avantor, Inc. reported a net sales of $1,623.8 million for Q3 2025, reflecting a decrease of 5.3% compared to Q3 2024, with an organic sales decline of 4.7% after accounting for foreign currency translation and M&A impacts [4][9] - The company experienced a net loss of $711.8 million in Q3 2025, a significant decline from a net income of $57.8 million in the same quarter of the previous year [5][22] - A non-cash goodwill impairment charge of $785 million was recorded, impacting the financial results significantly [6][25] - Avantor announced a $500 million share repurchase program, indicating confidence in its cash generation capabilities and commitment to long-term shareholder value [3][8] Financial Performance - Adjusted EBITDA for Q3 2025 was $267.9 million, with an adjusted EBITDA margin of 16.5% [5][25] - Adjusted net income was reported at $151.1 million, down from $175.2 million in Q3 2024, reflecting a decrease of 13.1% [5][25] - The diluted loss per share on a GAAP basis was $1.04, while the adjusted EPS was $0.22 [5][22] Operational Changes - The company is implementing strategic changes to enhance execution, accountability, and financial performance, including evolving its go-to-market approach and investing in manufacturing and supply chain [3][8] - Avantor is scrutinizing its portfolio to focus on opportunities that will drive the greatest value creation for customers and shareholders [3][8] Segment Results - The Laboratory Solutions segment reported net sales of $1.62 billion, a decrease of 5% compared to the previous year [8][9] - Adjusted Operating Income for the segment was $123.6 million, down from $151.5 million in Q3 2024, with an adjusted operating income margin of 11.3% [9][10]